Pembrolizumab is also approved as monotherapy for the treatment of R/M-HNC with PD-L1-expressing tumors (tumor proportion score “TPS” ≥ 50%) and cancer progression during or after prior platinum-based therapy in adults. Here, CD274 is linked to neoplasm.